Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Biotechnology

Healthcare
$10.19 -1.58%

-$0.19 today

Market cap
$859.56M
Beta
0.84
P/E (TTM)
-24.1
EPS (TTM)
-$0.49
52W Low $3.55High $26.95

Volume 0.99M

Average 1.49M

CRVS Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Corvus Pharmaceuticals, Inc.NASDAQ: CRVS

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$425.99M, compared with -$381.82M a year earlier.

Context

  • Retained earnings amounted to 168.2% of total assets at the end of Q1 FY2026, down 474.1 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -11.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$425.99M-3.3% QoQ
Last fiscal yearDec 2025
-$412.29M-3.8% YoY
Year agoMar 2025
-$381.82M-11.6% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.6%——
1 year-3.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(412.29M) USD
Year-over-year change
-3.8%

Retained Earnings vs competitors

How CRVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -11.6% is the 6th highest of 9, against a peer median of -7.6%.
  • Retained earnings amounts to 168.2% of total assets for CRVS, versus a peer median of 351.2%.
CRVS Competitors
Retained Earnings for CRVS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CGENCompugen Ltd.Mar 2026$0 USD——0.0%
ADAGAdagene Inc.Dec 2025-$328.79M USD-5.7%—420.1%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026-$425.99M USD-11.6%—168.2%
IPHAInnate Pharma S.A.Dec 2025-€435.36M EUR-12.7%—694.4%
CMPXCompass Therapeutics, Inc.Mar 2026-$449.49M USD-17.9%—219.1%
CTMXCytomX Therapeutics, Inc.Mar 2026-$730.2M USD-9.3%—203.2%
MGNXMacroGenics, Inc.Mar 2026-$1.28B USD-5.8%—588.0%
CHRSCoherus Oncology, Inc.Mar 2026-$1.42B USD+11.6%—534.3%
RCUSArcus Biosciences, Inc.Jun 2026-$1.7B USD-37.0%—184.4%
NKTRNektar TherapeuticsJun 2026-$3.85B USD-4.3%—351.2%
Peer median (excluding CRVS) —-7.6%—351.2%

Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents63.46M13.16M12.62M8.74M4.58M
Short-term Investments5.99M29.14M14.53M43.22M52.17M
Net Receivables539K633K63K216K374K
Inventory00000
Other Current Assets128K102K220K548K318K
Total Current Assets71.31M43.66M27.96M54.41M58.21M
Property, Plant & Equipment (Net)3.64M2.57M1.39M1.33M1.06M
Goodwill00000
Intangible Assets00000
Long-term Investments34.27M21.88M16.12M12.54M10.99M
Tax Assets00000
Other Non-current Assets236K129K89K632K855K
Total Non-current Assets38.14M24.58M17.6M14.5M12.91M
Total Assets109.46M68.24M45.55M68.91M71.12M
Account Payables1.57M1.98M1.53M2.58M2.49M
Short-term Debt0000403K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.97M1.27M929K30.02M5.85M
Total Current Liabilities9.69M10.75M6.87M35.4M9.38M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities2.6M1.37M0937K534K
Total Liabilities12.29M12.13M6.87M36.34M9.91M
Common Stock5K5K5K7K7K
Retained Earnings(266.38M)(307.69M)(334.72M)(397.01M)(412.29M)
Accumulated OCI1.87M(563K)(967K)(1.29M)(896K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity97.16M56.12M38.68M32.57M61.21M
Total Debt3.65M2.6M1.37M1.12M937K
Net Debt(59.81M)(10.56M)(11.25M)(7.62M)(3.64M)

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Intrinsic Alpha fair value

Locked

Current Price

$10.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.